Victoria P Werth MD

Dermatology•Philadelphia, PA

Dermatopathology

Professor of Dermatology, University Pennsylvania

Join to View Full Profile

3400 Spruce Street2 Rhoads PavilionPhiladelphia, PA 19104
Phone+1 215-662-2737
Fax+1 215-349-8339

Education & Training

NYU Grossman School of MedicineResidency, Dermatology, 1983 - 1986
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1980 - 1983
Johns Hopkins University School of MedicineClass of 1980

Certifications & Licensure

PA State Medical License 1989 - 2026
IL State Medical License 1982 - 1984
MD State Medical License 1980 - 1983
American Board of Dermatology Dermatology
American Board of Dermatology Dermatological Immunology/Diagnostic & Laboratory Immunology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Philadelphia Magazine Castle Connolly, 2008-2014
America's Top Doctors Castle Connolly, 2008-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Fellow (FAAD) American Academy of Dermatology
Fellow (FACR) American College of Rheumatology
Join now to see all

Clinical Trials

Use of Infliximab for the Treatment of Pemphigus Vulgaris Start of enrollment: 2006 Mar 01
Completed
Phase 2
Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris Start of enrollment: 1996 Nov 01
Terminated
Phase 2
Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Start of enrollment: 2007 Mar 01
Completed
Phase 2
Use of KC706 for the Treatment of Pemphigus Vulgaris Start of enrollment: 2007 Nov 01
Completed
Phase 2
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE) Start of enrollment: 2007 Nov 01
Completed
Not Applicable
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
RECRUITING
Photoprovocation Testing in Subjects With Cutaneous Lupus Start of enrollment: 2011 Dec 01
Completed
Not Applicable
Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. Start of enrollment: 2013 Jul 01
Completed
Phase 1, Phase 2
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Start of enrollment: 2015 Jun 01
Terminated
Phase 2
Autoimmune Blistering Diseases Study
RECRUITING
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Start of enrollment: 2018 Dec 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.
Sara Faghihi-Kashani, Akira Yoshida, Francisca Bozan, Giovanni Zanframundo, Davide Rozza
Arthritis & Rheumatology. 2025-04-01
Smoking status is a negative predictor of six-month cutaneous lupus activity trends: A prospective cohort study.
Tyler B Cepica, Lillian Xie, Daniella F Faden, Caroline J Stone, Rui Feng
Journal of the American Academy of Dermatology. 2025-04-01
The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project.
Giovanni Zanframundo, Eduardo Dourado, Iazsmin Bauer-Ventura, Sara Faghihi-Kashani, Akira Yoshida
Annals of the Rheumatic Diseases. 2025-03-18

Journal Articles

Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus
Scott A Elman, Kara Braudis, Hee Joo Kim, Victoria P Werth, JAMA Dermatology
Fatigue in Systemic Lupus Erythematosus and Other Autoimmune Skin Diseases
V P Werth, D Pearson, C J Kushner, The British Journal of Dermatology
Systemic Sclerosis: Current Concepts of Skin and Systemic Manifestations
David R Pearson, Victoria P Werth, ScienceDirect
Evaluation of the Reliability and Validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in Pediatric Cutaneous Lupus Among Pediatric De...
P J Kahn, D R Pearson, B Patel, V P Werth, Y E Chiu, The British Journal of Dermatology
Systemic Sclerosis: Current Concepts of Skin and Systemic Manifestations
David R Pearson, Victoria P Werth, Lisa Pappas-Taffer, Clinics in Dermatology
Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study
Victoria Werth, MD, Hindawi
The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus
Albrecht J, Taylor L, Berlin J, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G , McGinnis K, Richardson S, Treat J, Vittorio C, Voorhees AV, Werth VP, Journal of Investigative Dermatology, 2005
Join now to see all

Lectures

Recent Advances in Bullous Diseases
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019

Authored Content

Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusJune 2020
Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusJune 2020
Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusJune 2020

Press Mentions

Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus, Paving Way for Pivotal TrialsApril 1st, 2025
Trial Shows Dupilumab Reduces Itch, Disease Activity, Steroid Use in Bullous PemphigoidMarch 13th, 2025
TYK2 Inhibitor Scores Two Wins Outside Plaque PsoriasisMarch 10th, 2025
Join now to see all

Grant Support

Extracellular vesicles as a novel mediator for ultraviolet-B light induced photoaging and skin inflammation.PHILADELPHIA VA MEDICAL CENTER2023–2027
Extracellular vesicles as a novel mediator for ultraviolet-B light induced photoaging and skin inflammation.PHILADELPHIA VA MEDICAL CENTER2023–2027
Extracellular vesicles as a novel mediator for ultraviolet-B light induced photoaging and skin inflammation.PHILADELPHIA VA MEDICAL CENTER2023–2027
Extracellular vesicles as a novel mediator for ultraviolet-B light induced photoaging and skin inflammation.PHILADELPHIA VA MEDICAL CENTER2023–2027
Extracellular vesicles as a novel mediator for ultraviolet-B light induced photoaging and skin inflammation.PHILADELPHIA VA MEDICAL CENTER2023–2027
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)NEW YORK UNIVERSITY SCHOOL OF MEDICINE2022–2026
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)NEW YORK UNIVERSITY SCHOOL OF MEDICINE2022–2026
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.ZYLO THERAPEUTICS, INC.2023–2025
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.ZYLO THERAPEUTICS, INC.2023–2025
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.ZYLO THERAPEUTICS, INC.2023–2025
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositisUNIVERSITY OF PENNSYLVANIA2020–2025
Patient-Oriented Research In Skin Autoimmune DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2008–2012
Assess The Safety Of Pi-0824 In Patients With Pemphigus VulgarisNational Center For Research Resources2005
Patient-Oriented Research In Skin Autommune DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2001–2005